Intrinsic value of Theravance Biopharma - TBPH

Previous Close

$25.48

  Intrinsic Value

$0.53

stock screener

  Rating & Target

str. sell

-98%

Previous close

$25.48

 
Intrinsic value

$0.53

 
Up/down potential

-98%

 
Rating

str. sell

We calculate the intrinsic value of TBPH stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  25
  38
  57
  83
  116
  160
  215
  282
  363
  459
  569
  696
  839
  998
  1,174
  1,366
  1,573
  1,796
  2,034
  2,287
  2,554
  2,835
  3,131
  3,440
  3,763
  4,100
  4,450
  4,815
  5,194
  5,589
Variable operating expenses, $m
  117
  180
  269
  391
  551
  758
  1,017
  1,335
  1,718
  2,170
  2,695
  3,295
  3,972
  4,725
  5,556
  6,463
  7,445
  8,500
  9,627
  10,823
  12,088
  13,420
  14,818
  16,281
  17,810
  19,403
  21,063
  22,790
  24,585
  26,451
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  117
  180
  269
  391
  551
  758
  1,017
  1,335
  1,718
  2,170
  2,695
  3,295
  3,972
  4,725
  5,556
  6,463
  7,445
  8,500
  9,627
  10,823
  12,088
  13,420
  14,818
  16,281
  17,810
  19,403
  21,063
  22,790
  24,585
  26,451
Operating income, $m
  -92
  -142
  -212
  -308
  -435
  -598
  -802
  -1,053
  -1,355
  -1,712
  -2,126
  -2,599
  -3,132
  -3,727
  -4,382
  -5,098
  -5,872
  -6,704
  -7,593
  -8,537
  -9,534
  -10,585
  -11,687
  -12,841
  -14,047
  -15,304
  -16,613
  -17,975
  -19,391
  -20,863
EBITDA, $m
  -89
  -137
  -205
  -298
  -420
  -578
  -775
  -1,018
  -1,310
  -1,655
  -2,055
  -2,512
  -3,028
  -3,603
  -4,236
  -4,928
  -5,677
  -6,481
  -7,340
  -8,253
  -9,217
  -10,233
  -11,298
  -12,414
  -13,579
  -14,795
  -16,060
  -17,377
  -18,746
  -20,169
Interest expense (income), $m
  0
  12
  7
  14
  23
  36
  53
  75
  102
  136
  176
  224
  280
  343
  415
  495
  583
  679
  783
  894
  1,014
  1,140
  1,274
  1,415
  1,563
  1,718
  1,880
  2,048
  2,224
  2,407
  2,597
Earnings before tax, $m
  -104
  -149
  -226
  -331
  -470
  -650
  -877
  -1,155
  -1,491
  -1,888
  -2,350
  -2,879
  -3,476
  -4,142
  -4,877
  -5,680
  -6,551
  -7,487
  -8,487
  -9,550
  -10,674
  -11,859
  -13,102
  -14,404
  -15,765
  -17,184
  -18,661
  -20,199
  -21,798
  -23,460
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -104
  -149
  -226
  -331
  -470
  -650
  -877
  -1,155
  -1,491
  -1,888
  -2,350
  -2,879
  -3,476
  -4,142
  -4,877
  -5,680
  -6,551
  -7,487
  -8,487
  -9,550
  -10,674
  -11,859
  -13,102
  -14,404
  -15,765
  -17,184
  -18,661
  -20,199
  -21,798
  -23,460

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  254
  392
  586
  851
  1,200
  1,650
  2,215
  2,909
  3,743
  4,727
  5,870
  7,177
  8,651
  10,293
  12,102
  14,078
  16,216
  18,515
  20,969
  23,575
  26,330
  29,231
  32,276
  35,463
  38,792
  42,264
  45,879
  49,640
  53,551
  57,616
Adjusted assets (=assets-cash), $m
  254
  392
  586
  851
  1,200
  1,650
  2,215
  2,909
  3,743
  4,727
  5,870
  7,177
  8,651
  10,293
  12,102
  14,078
  16,216
  18,515
  20,969
  23,575
  26,330
  29,231
  32,276
  35,463
  38,792
  42,264
  45,879
  49,640
  53,551
  57,616
Revenue / Adjusted assets
  0.098
  0.097
  0.097
  0.098
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
  0.097
Average production assets, $m
  15
  24
  35
  51
  72
  99
  133
  175
  225
  285
  354
  432
  521
  620
  729
  848
  977
  1,115
  1,263
  1,420
  1,586
  1,761
  1,944
  2,136
  2,337
  2,546
  2,764
  2,990
  3,226
  3,471
Working capital, $m
  -54
  -84
  -126
  -183
  -258
  -354
  -476
  -624
  -803
  -1,015
  -1,260
  -1,541
  -1,857
  -2,209
  -2,598
  -3,022
  -3,481
  -3,974
  -4,501
  -5,061
  -5,652
  -6,275
  -6,928
  -7,613
  -8,327
  -9,072
  -9,848
  -10,656
  -11,495
  -12,368
Total debt, $m
  126
  250
  425
  663
  978
  1,383
  1,891
  2,515
  3,266
  4,152
  5,181
  6,357
  7,683
  9,161
  10,790
  12,568
  14,492
  16,561
  18,769
  21,115
  23,595
  26,206
  28,946
  31,815
  34,811
  37,935
  41,188
  44,574
  48,093
  51,752
Total liabilities, $m
  228
  353
  528
  766
  1,080
  1,485
  1,994
  2,618
  3,368
  4,255
  5,283
  6,459
  7,786
  9,263
  10,892
  12,670
  14,595
  16,663
  18,872
  21,218
  23,697
  26,308
  29,049
  31,917
  34,913
  38,037
  41,291
  44,676
  48,196
  51,854
Total equity, $m
  25
  39
  59
  85
  120
  165
  222
  291
  374
  473
  587
  718
  865
  1,029
  1,210
  1,408
  1,622
  1,851
  2,097
  2,358
  2,633
  2,923
  3,228
  3,546
  3,879
  4,226
  4,588
  4,964
  5,355
  5,762
Total liabilities and equity, $m
  253
  392
  587
  851
  1,200
  1,650
  2,216
  2,909
  3,742
  4,728
  5,870
  7,177
  8,651
  10,292
  12,102
  14,078
  16,217
  18,514
  20,969
  23,576
  26,330
  29,231
  32,277
  35,463
  38,792
  42,263
  45,879
  49,640
  53,551
  57,616
Debt-to-equity ratio
  4.960
  6.390
  7.250
  7.800
  8.150
  8.380
  8.540
  8.650
  8.730
  8.780
  8.830
  8.860
  8.880
  8.900
  8.920
  8.930
  8.940
  8.940
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -104
  -149
  -226
  -331
  -470
  -650
  -877
  -1,155
  -1,491
  -1,888
  -2,350
  -2,879
  -3,476
  -4,142
  -4,877
  -5,680
  -6,551
  -7,487
  -8,487
  -9,550
  -10,674
  -11,859
  -13,102
  -14,404
  -15,765
  -17,184
  -18,661
  -20,199
  -21,798
  -23,460
Depreciation, amort., depletion, $m
  3
  5
  7
  10
  14
  20
  27
  35
  45
  57
  71
  86
  104
  124
  146
  170
  195
  223
  253
  284
  317
  352
  389
  427
  467
  509
  553
  598
  645
  694
Funds from operations, $m
  -101
  -144
  -219
  -321
  -456
  -630
  -850
  -1,120
  -1,446
  -1,831
  -2,279
  -2,792
  -3,371
  -4,018
  -4,731
  -5,511
  -6,355
  -7,264
  -8,234
  -9,266
  -10,357
  -11,507
  -12,714
  -13,977
  -15,297
  -16,674
  -18,109
  -19,601
  -21,153
  -22,766
Change in working capital, $m
  -20
  -30
  -42
  -57
  -75
  -97
  -121
  -149
  -179
  -211
  -245
  -280
  -316
  -352
  -388
  -424
  -459
  -493
  -527
  -559
  -591
  -623
  -654
  -684
  -715
  -745
  -776
  -807
  -840
  -873
Cash from operations, $m
  -80
  -114
  -177
  -264
  -381
  -534
  -729
  -971
  -1,267
  -1,620
  -2,034
  -2,512
  -3,055
  -3,665
  -4,343
  -5,087
  -5,896
  -6,770
  -7,708
  -8,707
  -9,766
  -10,884
  -12,060
  -13,293
  -14,583
  -15,929
  -17,333
  -18,793
  -20,313
  -21,893
Maintenance CAPEX, $m
  -2
  -3
  -5
  -7
  -10
  -14
  -20
  -27
  -35
  -45
  -57
  -71
  -86
  -104
  -124
  -146
  -170
  -195
  -223
  -253
  -284
  -317
  -352
  -389
  -427
  -467
  -509
  -553
  -598
  -645
New CAPEX, $m
  -6
  -8
  -12
  -16
  -21
  -27
  -34
  -42
  -50
  -59
  -69
  -79
  -89
  -99
  -109
  -119
  -129
  -138
  -148
  -157
  -166
  -175
  -183
  -192
  -201
  -209
  -218
  -227
  -236
  -245
Cash from investing activities, $m
  -8
  -11
  -17
  -23
  -31
  -41
  -54
  -69
  -85
  -104
  -126
  -150
  -175
  -203
  -233
  -265
  -299
  -333
  -371
  -410
  -450
  -492
  -535
  -581
  -628
  -676
  -727
  -780
  -834
  -890
Free cash flow, $m
  -88
  -126
  -194
  -287
  -412
  -575
  -783
  -1,040
  -1,352
  -1,724
  -2,160
  -2,661
  -3,230
  -3,868
  -4,576
  -5,351
  -6,195
  -7,104
  -8,079
  -9,116
  -10,216
  -11,376
  -12,596
  -13,874
  -15,211
  -16,606
  -18,059
  -19,573
  -21,147
  -22,783
Issuance/(repayment) of debt, $m
  -98
  124
  175
  238
  315
  405
  508
  624
  751
  886
  1,029
  1,176
  1,326
  1,478
  1,629
  1,778
  1,925
  2,068
  2,209
  2,346
  2,480
  2,611
  2,740
  2,868
  2,996
  3,124
  3,254
  3,385
  3,520
  3,658
Issuance/(repurchase) of shares, $m
  301
  163
  245
  357
  505
  695
  933
  1,225
  1,574
  1,987
  2,464
  3,009
  3,623
  4,306
  5,058
  5,878
  6,764
  7,717
  8,733
  9,811
  10,950
  12,149
  13,407
  14,723
  16,098
  17,531
  19,023
  20,575
  22,189
  23,866
Cash from financing (excl. dividends), $m  
  203
  287
  420
  595
  820
  1,100
  1,441
  1,849
  2,325
  2,873
  3,493
  4,185
  4,949
  5,784
  6,687
  7,656
  8,689
  9,785
  10,942
  12,157
  13,430
  14,760
  16,147
  17,591
  19,094
  20,655
  22,277
  23,960
  25,709
  27,524
Total cash flow (excl. dividends), $m
  115
  161
  227
  308
  408
  525
  659
  809
  973
  1,149
  1,333
  1,524
  1,719
  1,915
  2,111
  2,304
  2,495
  2,681
  2,863
  3,040
  3,214
  3,384
  3,552
  3,718
  3,883
  4,049
  4,217
  4,387
  4,562
  4,741
Retained Cash Flow (-), $m
  -301
  -163
  -245
  -357
  -505
  -695
  -933
  -1,225
  -1,574
  -1,987
  -2,464
  -3,009
  -3,623
  -4,306
  -5,058
  -5,878
  -6,764
  -7,717
  -8,733
  -9,811
  -10,950
  -12,149
  -13,407
  -14,723
  -16,098
  -17,531
  -19,023
  -20,575
  -22,189
  -23,866
Prev. year cash balance distribution, $m
  287
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  101
  -1
  -19
  -49
  -98
  -171
  -274
  -416
  -602
  -838
  -1,131
  -1,485
  -1,904
  -2,391
  -2,947
  -3,573
  -4,270
  -5,036
  -5,870
  -6,771
  -7,736
  -8,765
  -9,855
  -11,005
  -12,214
  -13,481
  -14,806
  -16,188
  -17,627
  -19,125
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  97
  -1
  -16
  -40
  -76
  -124
  -185
  -260
  -346
  -439
  -537
  -634
  -724
  -803
  -865
  -908
  -929
  -927
  -904
  -860
  -800
  -727
  -646
  -561
  -475
  -393
  -318
  -250
  -192
  -144
Current shareholders' claim on cash, %
  50.0
  30.5
  18.7
  11.6
  7.3
  4.6
  3.0
  1.9
  1.2
  0.8
  0.5
  0.4
  0.2
  0.2
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

FINANCIAL RATIOS  of  Theravance Biopharma (TBPH)

Valuation Ratios
P/E Ratio -7
Price to Sales 27.5
Price to Book 3.8
Price to Tangible Book
Price to Cash Flow -13.6
Price to Free Cash Flow -13.3
Growth Rates
Sales Growth Rate 16.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -33.3%
Cap. Spend. - 3 Yr. Gr. Rate -7.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 63.7%
Total Debt to Equity 63.7%
Interest Coverage 0
Management Effectiveness
Return On Assets -40.7%
Ret/ On Assets - 3 Yr. Avg. -76.1%
Return On Total Capital -46.8%
Ret/ On T. Cap. - 3 Yr. Avg. -96.2%
Return On Equity -64.4%
Return On Equity - 3 Yr. Avg. -102.1%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 93.9%
Gross Margin - 3 Yr. Avg. 82.9%
EBITDA Margin -363.3%
EBITDA Margin - 3 Yr. Avg. -895.7%
Operating Margin -367.3%
Oper. Margin - 3 Yr. Avg. -911.3%
Pre-Tax Margin -369.4%
Pre-Tax Margin - 3 Yr. Avg. -908.4%
Net Profit Margin -389.8%
Net Profit Margin - 3 Yr. Avg. -932.7%
Effective Tax Rate -5.5%
Eff/ Tax Rate - 3 Yr. Avg. -2.9%
Payout Ratio 0%

TBPH stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the TBPH stock intrinsic value calculation we used $15.386 million for the last fiscal year's total revenue generated by Theravance Biopharma. The default revenue input number comes from 0001 income statement of Theravance Biopharma. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our TBPH stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for TBPH is calculated based on our internal credit rating of Theravance Biopharma, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Theravance Biopharma.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of TBPH stock the variable cost ratio is equal to 473.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for TBPH stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Theravance Biopharma.

Corporate tax rate of 27% is the nominal tax rate for Theravance Biopharma. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the TBPH stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for TBPH are equal to 62.1%.

Life of production assets of 2.3 years is the average useful life of capital assets used in Theravance Biopharma operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for TBPH is equal to -221.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $115.178 million for Theravance Biopharma - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 54.854 million for Theravance Biopharma is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Theravance Biopharma at the current share price and the inputted number of shares is $1.4 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 43.21 34.10  hold
JNJ Johnson&Johnso 144.50 176.79  buy
MRK Merck&Co 74.84 33.05  str.sell

COMPANY NEWS

▶ Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more   [Nov-12-18 10:21AM  American City Business Journals]
▶ Theravance Bio: 3Q Earnings Snapshot   [06:12PM  Associated Press]
▶ Health Care Digest: Upsized record IPO, e-cigarette questions, a CEO Dance and more   [Oct-08-18 10:29AM  American City Business Journals]
▶ 3 Small Biotech Stocks to Watch in the Fourth Quarter   [Oct-07-18 01:00PM  TheStreet.com]
▶ Theravance Bio: 2Q Earnings Snapshot   [07:23AM  Associated Press]
▶ High Growth Stocks To Profit From   [May-10-18 12:02PM  Simply Wall St.]
▶ Theravance Bio: 1Q Earnings Snapshot   [May-08-18 06:53PM  Associated Press]
▶ Should You Buy Theravance Biopharma Inc (NASDAQ:TBPH) Now?   [Mar-30-18 08:39AM  Simply Wall St.]
▶ Theravance Bio reports 4Q loss   [05:04AM  Associated Press]
▶ Why Theravance Biopharma Shares Are Soaring   [Feb-07-18 11:10AM  24/7 Wall St.]
▶ Theravance Bio reports 3Q loss   [Nov-07-17 05:31PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.